BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23806383)

  • 1. The changing face of percutaneous image-guided biopsy: molecular profiling and genomic analysis in current practice.
    Marshall D; Laberge JM; Firetag B; Miller T; Kerlan RK
    J Vasc Interv Radiol; 2013 Aug; 24(8):1094-103. PubMed ID: 23806383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized oncology in interventional radiology.
    Abi-Jaoudeh N; Duffy AG; Greten TF; Kohn EC; Clark TW; Wood BJ
    J Vasc Interv Radiol; 2013 Aug; 24(8):1083-92; quiz 1093. PubMed ID: 23885909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epistatic interactions and drug response.
    Weigelt B; Reis-Filho JS
    J Pathol; 2014 Jan; 232(2):255-63. PubMed ID: 24105606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The genetic complexity of common cancers and the promise of personalized medicine: is there any hope?
    Arnedos M; Vielh P; Soria JC; Andre F
    J Pathol; 2014 Jan; 232(2):274-82. PubMed ID: 24114621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical applications of The Cancer Genome Atlas project (TCGA) for squamous cell lung carcinoma.
    Devarakonda S; Morgensztern D; Govindan R
    Oncology (Williston Park); 2013 Sep; 27(9):899-906. PubMed ID: 24282988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
    Pilotto S; Peretti U; Novello S; Rossi G; Milella M; Giaj Levra M; Ciuffreda L; Massari F; Brunelli M; Tortora G; Bria E
    Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomics, personalized medicine and cancer practice.
    Dancey J
    Clin Biochem; 2012 Apr; 45(6):379-81. PubMed ID: 22424082
    [No Abstract]   [Full Text] [Related]  

  • 9. Comprehensive genomic profiling of relapsed and metastatic adenoid cystic carcinomas by next-generation sequencing reveals potential new routes to targeted therapies.
    Ross JS; Wang K; Rand JV; Sheehan CE; Jennings TA; Al-Rohil RN; Otto GA; Curran JC; Palmer G; Downing SR; Yelensky R; Lipson D; Balasubramanian S; Garcia L; Mahoney K; Ali SM; Miller VA; Stephens PJ
    Am J Surg Pathol; 2014 Feb; 38(2):235-8. PubMed ID: 24418857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatic alterations as the basis for resistance to targeted therapies.
    Blair BG; Bardelli A; Park BH
    J Pathol; 2014 Jan; 232(2):244-54. PubMed ID: 24114654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular prognostication of non-small cell lung cancer.
    Tsao MS; Jablons DM
    Semin Thorac Cardiovasc Surg; 2013; 25(1):4-7. PubMed ID: 23800523
    [No Abstract]   [Full Text] [Related]  

  • 12. Changing pathology with changing drugs: tumors of the gastrointestinal tract.
    Cervera P; Fléjou JF
    Pathobiology; 2011; 78(2):76-89. PubMed ID: 21677471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biology-driven phase II trials: what is the optimal model for molecular selection?
    Andre F; Delaloge S; Soria JC
    J Clin Oncol; 2011 Apr; 29(10):1236-8. PubMed ID: 21343554
    [No Abstract]   [Full Text] [Related]  

  • 14. Personalized Medicine: Genomics Trials in Oncology.
    Hayes DF; Schott AF
    Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Array-based pharmacogenomics of molecular-targeted therapies in oncology.
    Sanoudou D; Mountzios G; Arvanitis DA; Pectasides D
    Pharmacogenomics J; 2012 Jun; 12(3):185-96. PubMed ID: 22249357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving evidence developed from population-level experience with targeted agents.
    McClellan MB; Daniel GW; Dickson D; Perlmutter J; Berger DP; Miller V; Nussbaum S; Malin J; Romine MH; Schilsky RL
    Clin Pharmacol Ther; 2015 May; 97(5):478-87. PubMed ID: 25676878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospects for molecular staging of non-small-cell lung cancer from genomic alterations.
    Tomaszek SC; Huebner M; Wigle DA
    Expert Rev Respir Med; 2010 Aug; 4(4):499-508. PubMed ID: 20658911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized oncology: genomic screening in phase 1.
    Tuxen IV; Jønson L; Santoni-Rugiu E; Hasselby JP; Nielsen FC; Lassen U
    APMIS; 2014 Aug; 122(8):723-33. PubMed ID: 25046202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next generation sequencing applications in cancer research.
    Zhang W; Nykter M; Chen K
    Cancer Lett; 2013 Nov; 340(2):149-50. PubMed ID: 23764479
    [No Abstract]   [Full Text] [Related]  

  • 20. Personalizing oncology: perspectives and prospects.
    Mendelsohn J
    J Clin Oncol; 2013 May; 31(15):1904-11. PubMed ID: 23589547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.